retatrutide facts A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity | European Journal of Clinical Pharmacology Buy Retatrutide (12mg) | Order

And prices are coming down for other weight-loss drugs

PDUFA Date and Launch If the NDA is filed Q4 2026, expect FDA action around late 2027 (priority review) or Q1 2028 (standard review), with commercial launch following 13 months later for manufacturing and distribution setup

What if I faint

UK SmPCs advise that patients should report any symptoms such as a neck lump, hoarseness, or difficulty swallowing to their doctor GIP receptor-mediated effects are not yet fully characterised in humans

Agency feedback can mean more data collection or further analysis, which can shift this timeline

The real key is going to be side effects over time, if retatrutide is like other drugs in the class then the side effects should decrease with time, but unfortunately, we dont have that today, at this point I have some questions and minor concerns but without the data over time its hard to speculate about tolerability further beyond saying its similar to other drugs in the class